



an Open Access Journal by MDPI

## Diagnosis, Pathogenesis and Treatment of Pancreatic Ductal Adenocarcinoma

Guest Editors:

**Dr. Teresa Perra**

Department of Medicine, Surgery and Pharmacy, Unit of General Surgery, University of Sassari, 07100 Sassari, Italy

**Prof. Alberto Porcu**

Department of Medicine, Surgery and Pharmacy, Unit of General Surgery, University of Sassari, 07100 Sassari, Italy

Deadline for manuscript submissions:

**closed (30 April 2025)**

### Message from the Guest Editors

Pancreatic ductal adenocarcinoma (PDAC) is the most common form of pancreatic cancer, originating from the epithelial cells of the main pancreatic duct.

The pathogenesis of PDAC is not fully understood, but includes various risk factors such as genetic predisposition, chronic pancreatitis, smoking, obesity, and diabetes. Genetic mutations play a significant role in the development of PDAC, with KRAS, TP53, and CDKN2A among the most commonly altered genes.

Treatment for PDAC depends on the stage of the cancer and the patient's overall health status. Early stage disease may be treated with surgical resection, while later stages or metastatic PDAC might require chemotherapy, radiation therapy, or targeted therapy. Novel treatment approaches, such as immunotherapy and personalized medicine, are being explored in order to improve patient outcomes.

This Special Issue aims to provide an overview of the advancements in preclinical and clinical practices in the field of the treatment of PDAC. We invite authors to submit original research and review articles focusing on this important topic.



[mdpi.com/si/200638](https://mdpi.com/si/200638)

# Special Issue



an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with article processing charges (APC) paid by authors or their institutions.

**High Visibility:** indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPLus / SciFinder*, and other databases.

**Journal Rank:** JCR - Q2 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](https://twitter.com/Biomed_MDPI)